Revolutionizing Gene Therapy Manufacturing: Viralgen’s Pro10™ Cell Line Improves Recombinant Adeno-Associated Virus Production Efficiency and Scalability

A Unique Mammalian Suspension Technology Enhances Scalable rAAV Production with Pro10 Cell Line

Viralgen has developed a new technology, the Pro10™ cell line, to improve the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. This proprietary mammalian suspension technology enables scalable and robust production of rAAVs, addressing the challenges faced in large-scale manufacturing of AAV gene therapies.

The Pro10™ cells have been fully characterized and licensed for gene therapy development by other biopharma companies. They have been optimized for rAAV production and successfully scaled up to 2000L, demonstrating consistent and reproducible cell growth rates. The cells exhibit similar productivity in small and large-scale bioreactors and can produce different AAV serotypes.

The HEK293 derived animal component-free suspension Pro10™ cell line is described in full in the PDF, which highlights its ability to reduce process development time and costs. This innovative technology is a promising advancement in the field of gene therapy manufacturing, offering a solution to the challenges faced in large-scale production of AAV vectors.

Sophia Reynolds

As a content writer at, I'm always on the lookout for the next intriguing story to share with our audience. With a passion for crafting engaging and informative content, I delve into a variety of topics ranging from breaking news to feature pieces. My goal is to captivate readers through my words and keep them coming back for more. When I'm not typing away at my keyboard, you can find me exploring new coffee shops, diving into a good book, or taking long walks in nature. Join me on this journey of storytelling and discovery at - where every word has the power to inform and inspire.

Learn More →

Leave a Reply